MedTrace Logo

Lovaza's Effect on the Activation of Platelets

NCT00515541 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2013-07-09

Study results available
· View outcomes & findings →

Summary

This study is to determine the effects of Lovaza in platelet function studies

Conditions

Interventions

DRUG

Lovaza

First 6 weeks period take 1 gram Lovaza capsule daily 2nd 6 weeks period take 2 grams of Lovaza (2 1 gram capsules) daily 3rd 6 weeks period take 4 grams of Lovaza (4 1 gram capsules) daily 4th 6 weeks period take 8 grams of Lovaza (8 1 gram capsules) daily

Sponsors & Collaborators

  • Reliant Pharmaceuticals

    collaborator INDUSTRY

  • Invitrox

    lead INDUSTRY

Principal Investigators

  • Mauricio Cohen, MD · University of North Carolina, Chapel Hill

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2009-06-30
Completion
2009-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00515541 on ClinicalTrials.gov